BioAge Labs has dosed the first participant in QUELL-DME, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor, in adults with diabetic macular edema. The target was identified not through ophthalmology but through human aging cohort data, where lower NLRP3 activity tracked with slower aging and longer lifespan. The three-arm design tests the drug as monotherapy and as an add-on to anti-VEGF injections, with vision change at 12 weeks as the primary endpoint and topline results expected in the second half of 2027.
Key Points
- Oral NLRP3 inhibitor BGE-102 enters Phase 2 for diabetic macular edema
- Target identified in aging cohorts showing lower NLRP3 in longer-lived people
- Three-arm trial tests monotherapy and anti-VEGF add-on; results 2027
Longevity Analysis
NLRP3 sits upstream of the inflammatory cascade implicated in cardiovascular, metabolic, neurodegenerative and retinal disease, making it one of the few targets where a single intervention plausibly addresses multiple age-related endpoints at once. The discovery route matters as much as the molecule: signals drawn from people aging unusually well pointed to a pathway that conventional disease-specific research had not prioritized for the eye, and the downstream consequences — IL-1β and IL-18 release, vascular leakage, breakdown of the blood-retinal barrier — are the immune system's defensive machinery operating without an off switch. An oral once-daily alternative to repeated intravitreal injections also addresses the adherence failure that undermines current care, where the barrier to benefit is not efficacy but whether patients continue treatment at all.
Original published by Longevity.Technology, by Kyle Umipig.